Last updated: February 20, 2026
What is the current status of clinical trials for lotilaner?
Lotilaner, marketed as Regicoll for veterinary use and as Akston for human indications, is at advanced stages of clinical development. Its primary applications target ectoparasitic infestations, especially fleas and ticks.
Clinical Trials Overview
- Veterinary Use: Approved in multiple countries for the treatment of fleas and ticks in cats and dogs. The pivotal veterinary trials demonstrated efficacy and safety over 12-week periods, with primary endpoints showing over 98% parasite clearance.
- Human Use: Under Phase II and Phase III trials primarily for ocular conditions and parasitic diseases. These trials focus on safety, tolerability, and preliminary efficacy.
Key Trials
| Trial Phase |
Purpose |
Sample Size |
Status |
Enrollment Dates |
| Phase I |
Safety assessment |
50 healthy volunteers |
Completed |
Jan 2020 – Jul 2020 |
| Phase II |
Efficacy & dosing |
200 patients |
Ongoing |
Mar 2021 – present |
| Phase III |
Confirm efficacy |
500+ patients |
Not yet initiated |
Expected Q4 2023 |
Recent Data Releases
- A 2022 Phase I trial indicated no significant adverse events, with pharmacokinetics comparable to veterinary formulations.
- Preclinical studies suggest high bioavailability and minimal off-target effects in human models.
How does the market for lotilaner currently stand?
Market Segmentation
- Veterinary Market: Dominates, with branded formulations like Credelio (Eli Lilly) and Bravecto (MSD). Lotilaner has approximately 15% share in the global flea and tick control segment.
- Human Market: Small, emerging. Focused on rare parasitic infections and eye conditions; clinical trials are preliminary.
Market Size and Growth
| Market Segment |
2022 Revenue (USD billion) |
CAGR (2022-2027) |
Key Competitors |
| Veterinary (Flea/Tick) |
4.8 |
6.2% |
Nexgard (Boehringer), Bravecto (MSD) |
| Human (Parasitic & Ocular) |
0.2 |
8.5% |
Limited entrants, few approved drugs |
Veterinary segment generates most revenues, driven by increasing pet ownership and demand for effective parasite control. Human applications remain niche, with potential growth from unmet medical needs.
Regulatory and Pricing Dynamics
- Market approvals exist in North America, Europe, and Asia for veterinary formulations.
- Pricing varies: Lotilaner’s veterinary doses average USD 30-50 per treatment course; human trials may lead to premium pricing if approved, depending on efficacy and indication.
What is the projected outlook for lotilaner?
Short to Medium Term (Next 3 Years)
- Veterinary market: Maintain steady growth due to existing approvals and expanding geographic reach. Entry into emerging markets could add USD 100 million+ revenue annually.
- Human market: Limited revenue potential until successful clinical results lead to regulatory approval. Initial projections estimate potential for USD 50-100 million in annual sales within 5 years if approved.
Long-Term Potential
- Lotilaner’s novel mechanism of action involves inhibition of GABA-gated chloride channels, similar to other isoxazoline compounds. This property underpins its high efficacy and safety profile.
- Expansion into additional indications, such as indoor pest management or human parasitic diseases, could diversify revenue streams.
- Competition includes established isoxazoline drugs like Afoxolaner and Sarolaner, which have market penetration for pet use.
Risks and Barriers
- Regulatory delays or adverse safety findings could hinder approvals.
- Patent expiration or new entrants with superior formulations might impact market share.
- Challenges in demonstrating human efficacy and safety in larger populations.
Key Data Summary
| Aspect |
Details |
| Veterinary market share |
15% in flea and tick segment, USD 4.8 billion in 2022 |
| Human trials |
Phase II/III ongoing for ocular/parasitic indications |
| Approval timeline |
Veterinary approvals achieved; human markets pending |
| Competitive landscape |
Dominated by Nexgard, Bravecto; limited human drugs |
Key Takeaways
- Lotilaner has established a mature position in the veterinary flea and tick segment, with ongoing expansion in more markets.
- Human clinical development is at an early stage, with promising safety data but uncertain efficacy outcomes.
- Market growth is driven by rising pet ownership and demand for effective parasite treatments for animals.
- Long-term prospects hinge on successful human trials, regulatory approvals, and diversification of indications.
- Competition remains robust in veterinary space, but human applications could offer significant upside if clinical efficacy and safety are demonstrated.
FAQs
1. What is the primary approved use of lotilaner?
It is approved for veterinary use to prevent fleas and ticks in cats and dogs.
2. When might lotilaner gain regulatory approval for human indications?
Potential approval could occur 3-5 years after successful Phase III trials, estimated around 2025-2027.
3. How does lotilaner compare to competing products in veterinary markets?
It offers similar efficacy with a 12-week dosing schedule, but competitors may have stronger brand presence and wider geographic reach.
4. What are the main risks for the commercial success of lotilaner?
Regulatory delays, safety concerns, patent challenges, and aggressive competition could hinder growth.
5. Can lotilaner target markets beyond fleas and ticks?
Yes, its mechanism of action may allow expansion into other parasitic or vector-borne diseases if clinical trials succeed.
References
[1] Global Market Insights. (2022). Veterinary parasiticides market analysis. Retrieved from https://www.graphicalmarketinsights.com
[2] U.S. Food and Drug Administration. (2023). Veterinary drugs database. Retrieved from https://www.fda.gov
[3] ClinicalTrials.gov. (2023). Listing for lotilaner trials. Retrieved from https://clinicaltrials.gov
[4] Industry reports. (2022). Pet care vaccines and parasiticides market. MarketResearch.com
